Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 1/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.54 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.53 |
| ▸ | ADK | P55263 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20925483 | 0.86 | ABL1 (0.55) | ADK | |
| SCHEMBL7990561 | 0.85 | LMNA (0.68) | HIF1ASLC29A1ADKALDH1A1LMNA | |
| SCHEMBL13820258 | 0.84 | ADORA1 (0.78) | ADORA1SLC29A1ALDH1A1LMNAGLA | |
| SCHEMBL18696325 | 0.84 | ADORA1 (0.51) | ADORA1SLC29A1ALDH1A1LMNAGLA | |
| SCHEMBL23637142 | 0.84 | ADORA1 (0.51) | ADORA1SLC29A1ALDH1A1LMNAGLA | |
| SCHEMBL24390241 | 0.84 | ADORA1 (0.78) | ADORA1SLC29A1ALDH1A1LMNAGLA | |
| SCHEMBL16609165 | 0.84 | ADORA1 (0.78) | ADORA1SLC29A1ALDH1A1LMNAGLA | |
| SCHEMBL3395259 | 0.84 | ADORA1 (0.78) | ADORA1SLC29A1ALDH1A1LMNAGLA | |
| SCHEMBL22349482 | 0.83 | HIF1A (0.56) | HIF1ASLC29A1ADKALDH1A1LMNA | |
| SCHEMBL18862688 | 0.83 | HIF1A (0.56) | HIF1ASLC29A1ADKALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3150593-B1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | DANA FARBER CANCER INST INC (US) | 2019-04-24 | — | — | EP | disclosed |